Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
Holding AGIO?
Track your performance easily
AGIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.96 - $62.58
Previous Close$33.4
Volume99.54K
Average Volume (3M)775.66K
Market Cap
$1.86B
Enterprise Value$960.89M
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$60.83M
Price to Earnings (P/E)2.9
Beta2.09
Next Earnings
Feb 13, 2025EPS Estimate
-$1.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.37
Shares Outstanding57,030,195
10 Day Avg. Volume1,100,484
30 Day Avg. Volume775,663
Standard Deviation0.13
R-Squared0.10
Alpha0.00568
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.17
Price to Sales (P/S)57.95
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.23
Enterprise Value/Gross Profit40.13
Enterprise Value/Ebitda-2.56
Forecast
1Y Price Target
$58.67Price Target Upside80.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Agios Pharma News
PremiumCompany Announcements
Agios Pharmaceuticals Reports Robust Q3 2024 ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsMitapivat's RISE-UP trial will be successful on the co-primary endpoint of VOC reduction, support multi-billion dollar sales, and make AGIO shares a top performer.
Drug Approval And AdoptionThe real value driver for Agios will be worldwide approval and adoption of Pyrukynd in thalassemia and sickle cell disease.
Financial PerformanceAgios received $1.1B due to vorasidenib's approval, leading to a net income of $948MM.
Bears Say
Clinical Trials And Safety ConcernsThe company disclosed three additional cases of hepatocellular injury for mitapivat in the open label portions of the ENERGIZE and ENERGIZE-T trials.
Market CompetitionShare weakness is likely also driven by PKR activator competitor readout from Novo Nordisk, which demonstrated comparable performance in VOC reduction and hemoglobin response.
Regulatory ChallengesThe withdrawal of Oxbryta increases the likelihood that regulators will need to see a definitive clinical benefit as a condition for approval, raising the regulatory bar.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $20.96 and its highest was $62.58 in the past 12 months.
What is Agios Pharma’s market cap?
Currently, no data Available
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Feb 13, 2025 which is in 45 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Oct 31, 2024. The company reported $16.22 earnings per share for the quarter, beating the consensus estimate of $15.216 by $1.004.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -$1.69.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 57,030,193 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of $16.22 in its last earnings report, beating expectations of $15.216. Following the earnings report the stock price went down -4.039%.
Which hedge fund is a major shareholder of Agios Pharma?
Among the largest hedge funds holding Agios Pharma’s share is Farallon Capital Management, L.L.C.. It holds Agios Pharma’s shares valued at 252M.
---
Agios Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.67 (80.25% Upside)
$58.67 (80.25% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 49.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.29%
12-Months-Change
Fundamentals
Return on Equity
53.65%
Trailing 12-Months
Asset Growth
77.89%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
---
AGIO Company Deck
---
AGIO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant milestone achievements, strong financial positioning, and promising advancements in clinical trials. However, challenges remain, particularly in pediatric PK deficiency and the sickle cell community. Overall, Agios appears well-positioned for future growth and product launches.Read More>---
AGIO Stock 12 Month Forecast
Average Price Target
$58.67
▲(80.25% Upside)
Technical Analysis
Best Analysts Covering AGIO
1 Year
1 Year Success Rate
14/23 ratings generated profit
1 Year Average Return
+19.00%
assigned a buy rating 22 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +19.00% per trade.
---